CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...

Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last "Hold" rating in November 2024. I will evaluate Heron's investment merits based on its full year and Q4 2024 ...

Earnings call Heron Therapeutics reported Q3 2025 revenue of $38.2M (+YoY), with Adjusted EBITDA of $1.5M. ZYNRELEF and APONVIE sales surged 49% and 173% YoY, respectively. Management reaffirmed FY25 ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.

Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01. Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 ...

Heron Therapeutics, Inc. (NASDAQ: HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.